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NOTCH2 is a transmembrane receptor that is part of the Notch receptor family, known for 
controlling cell differentiation and function. Notch receptors play a crucial role in skeletal 
development and bone homeostasis. Hajdu Cheney Syndrome (HCS) is a rare monogenic disorder 
affecting the skeleton caused by a gain-of-function mutation in NOTCH2. Antisense 
oligonucleotides (ASO) are sequence-specific single-stranded nucleic acids that bind to target 
mRNA and initiate mRNA degradation. While previous work has explored the role of Notch2 
ASOs in osteoblasts and osteoclasts, this paper explores the role of Notch2 and Notch2 ASOs in 
cells of cartilage tissue. The effect of Notch2 ASOs on Notch2 were tested in chondrocytes of a 
murine model of HCS (Notch2tm1.1Ecan) in vitro and in vivo. Notch2 ASO downregulated Notch2 
in chondrocytes of both Notch2wt/wt mice and Notch2tm1.1Ecan mice. Notch target genes Hes1, Hey1, 
Hey2, and HeyL were amplified in Notch2tm1.1Ecan mice, indicating the presence of the HCS gain-
of-function Notch2 mutation. Notch2 ASOs significantly downregulated Notch2 and Notch target 
genes in chondrocytes from Notch2tm1.1Ecan mice. The mutant gene Notch26955C>T was only detected 
in Notch2tm1.1Ecan mice and was downregulated by a mutant specific Notch26955C>T ASO. In 
conclusion, Notch2 ASOs successfully downregulate Notch2, Notch26955C>T, and Notch target 
genes in mouse chondrocytes. 
 
INTRODUCTION 
Notch signaling is fundamental to many different tissues. Gain or loss of elements of Notch 
signaling may result in a number of human disorders, including developmental diseases, immune 
disorders, cancer, and skeletal diseases (1,2). In mammals, there are four Notch transmembrane 
receptors (Notch1-4), all expressed in skeletal cells to varying degrees. NOTCH1 and NOTCH2 
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are known to be expressed by cells of the osteoblast and osteoclast lineage, and NOTCH3 is 
expressed by osteoblasts and osteocytes, but not by cells of the osteoclast lineage. NOTCH4 is 
expressed in skeletal cells to a lesser extent and its functions are not as well known (3). NOTCH1 
inhibits, while NOTCH2 induces, osteoclastogenesis and bone resorption (4). Osteoclastogenesis 
is the development of osteoclasts from macrophages, and bone resorption is the process in which 
osteoclasts break down the tissue in bones and release the minerals to blood (5). NOTCH2 also 
impairs osteoblast maturation, which are responsible for bone formation (3). NOTCH3 induces 
osteoclastogenesis by indirect mechanisms (6). Notch receptors are activated when interacting 
with one of the five transmembrane ligands on a neighboring cell (Jagged1, Jagged2, Delta-like1, 
Delta-like3, and Delta-like4). This paper focuses on NOTCH2 and uses JAGGED1 to induce 
Notch activation. JAGGED1, encoded by JAG1, is a Notch ligand that is prevalent in skeletal cells. 
JAGGED1 binds to and activates NOTCH2, among other Notch receptors (3, 7, 8). 
 
Notch are transmembrane receptors with a complex structure. The extracellular domain is 
responsible for interacting with Jagged or Delta-like ligands. In between the extracellular domain 
and the transmembrane domain is the negative regulatory region (NRR), a site where cleavage 
occurs after activation. The Notch intracellular domain (NICD) contains nuclear localization 
sequences, required to regulate transcription (3). On the C-terminus of Notch lies the proline- (P), 
glutamic acid- (E), serine- (S) and threonine- (T)- rich (PEST) domain (13). The PEST domain is 
targeted by ubiquitin ligases for the proteasomal degradation of Notch (1). Each Notch receptor 
carries out distinct functions in skeletal and non-skeletal cells. This is due to different patterns of 
cellular expression, variation in the affinity of the Notch extracellular domain to the Delta-like and 
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Jagged ligands, and variation in the NICD and hence diversified interaction between the NICD 
and its nuclear targets. 
 
Notch receptors are activated upon short-range cell-cell interaction with Jagged or Delta-like 
ligands. Upon activation, the Notch receptor undergoes two proteolytic cleavage events. The first 
is catalyzed by the ADAM-family of metalloproteases, whereas the second cleavage is catalyzed 
by γ-secretase, releasing the NICD (9). The NICD is then released into the cell where it translocates 
to the nucleus to associate with DNA-bound proteins (1). In the absence of a Notch signal and 
hence NICD, the recombination signal-binding protein for immunoglobulin kappa J (RBP-Jκ) 
represses Notch target genes through the recruitment of corepressor complexes (2). The NICD 
associates with RBP-Jκ and mastermind (MAML) to activate transcription of Notch target genes 
(10, 11).  After transcription is activated, the NICD is released and degraded by cell proteosomes. 
 
Hairy/Enhancer of split family genes (Hes) and Hes-related with YRPW motif (Hey), are well-
established Notch target genes expressed in multiple cell types that encode transcription factors 
(12). There are seven Hes proteins (Hes1-7), and all of them except Hes2 and Hes3 are targets of 
the Notch canonical signaling pathway. There are three Hey transcription factors (Hey1, Hey2, and 
HeyL), all targets of Notch (4). The Notch target genes that are analyzed in this paper are Hes1, 
Hey1, Hey2, and HeyL. Hes1 preserves the undifferentiated state of precursor cells during 
development and throughout cell life. Hes1, Hey1, Hey2, and HeyL have all been studied in the 
skeleton and cartilage and have been shown to be expressed during chondrogenesis and 





Figure 1. The Notch canonical signaling pathway, shown with NOTCH2. JAGGED1 binds to 
NOTCH2 receptor, releasing the NICD into the cell. The NICD interacts with RBPJ and MAML 
to enhance transcription of target genes Hes1, Hes4-7, and Hes-related family Hey1, Hey2, and 
HeyL. The Notch target genes shown in this figure and investigated in the paper are Hes1, Hey1, 
Hey2, and HeyL. Note: This is not a comprehensive diagram of all of the components involved in 
the Notch signaling pathway, but rather the key points as described in this paper. 
 
Hajdu Cheney Syndrome (HCS) is a monogenic disorder caused by gain-of-function NOTCH2 
pathogenic variants. HCS is a disease in humans characterized by osteoporosis, bone fractures, 
acro-osteolysis, wormian bones, and craniofacial developmental defects (15). As it is caused by 
an overactive NOTCH2 protein, HCS causes increased osteoclastogenesis and bone resorption in 
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mice (16). HCS is inherited as autosomal dominant and is associated with a truncated NOTCH2 
protein. The mutant NOTCH2 protein is truncated directly upstream of the sequences coding for 
the PEST domain, therefore creating a functional protein with a constitutively active NICD (17). 
Without the PEST domain, the NICD is not degraded by cell proteosomes and is stable within the 
cell, therefore gain-of-function. A mouse model heterozygous for this HCS mutation has been 
previously created and termed Notch2tm1.1Ecan. The mouse line harbors a 6955C>T substitution in 
Notch2 (7). This nucleotide substitution codes for a Q2319X amino acid change (a stop codon) in 
the sequence upstream of the PEST domain and resulting in a truncated protein of 2318 amino 
acids (17).  
 
Antisense oligonucleotides (ASO) are short and single-stranded nucleotides that alter RNA by 
binding to RNA sequences directly and inducing RNA degradation by RNase H, therefore 
modifying protein expression (18, 19, 20). Notch2 antisense oligonucleotides have been shown to 
downregulate Notch2 in cells of the spleen, kidney, and femur from Notch2wt/wt mice. In subsequent 
experiments, the Notch target genes Hes1, Hey1, Hey2, and HeyL were shown to be induced in 
bone extracts from mutant Notch2tm1.1Ecan mice and suppressed upon subcutaneous administration 




Figure 2. The process by which antisense oligonucleotides (ASO) facilitate mRNA degradation 
through recruitment of RNase H. 
 
Chondrocytes are specialized cells that function to produce, sustain, and degrade the cartilage 
extracellular matrix (22). Chondrogenesis is the process by which cartilage is formed: 
mesenchymal cells, a type of multipotent stem cell, differentiate into chondrocytes. (23).  
Chondrocytes in the hyaline cartilage undergo proliferation, hypertrophy, and apoptosis to be 
gradually replaced by bone in a process known as endochondral ossification. The cartilaginous 
scaffold that results from this allows for osteoblasts to replace the cartilage with bone. This process 
forms the appendicular skeleton and parts of the axial skeleton. Bone is formed and remodeled 
throughout one’s lifetime through coordination of osteoblasts and osteoclasts (24). Notch signaling 
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plays a key role in the life cycle of chondrocytes. Notch signaling has been shown to suppress 
chondrogenesis and promote the onset of chondrocyte hypertrophy, and it was shown that Notch2 
controls the inhibitory effects of Notch on skeletal development (14, 25). Additionally, NOTCH2 
gain-of-function has been documented in femoral heads of Notch2tm1.1Ecan mice and was shown to 
sensitize Notch2tm1.1Ecan mice to osteoarthritis, a disease characterized by cartilage degradation 
(26). 
 
Because Notch signaling is involved in chondrocyte maturation and degradation, we asked the 
question as to whether Notch2 ASO would downregulate Notch2 and Notch target genes in 
chondrocytes from Notch2tm1.1Ecan mice. Successful downregulation of Notch2 in mice harboring 
HCS could help to correct the effects of the gain-of-function HCS mutation. The effects of Notch2 
ASO treatment on Notch2, Notch26955C>T, and Notch target genes Hes1, Hey1, Hey2, and HeyL, 




Notch2tm1.1Ecan mice were created previously in a C57BL/6 background to harbor a point 6955C>T 
mutation in Notch2. Notch2tm1.1Ecan mice were crossed with wild type C57BL/6 mice for a yield of 
50% heterozygous mutant and 50% wild type newborns. Newborn mice were tattooed on feet for 
identification and their tails were snipped for genotyping. DNA was extracted from the tails using 
the HotSHOT DNA extraction method (27). Genotyping was conducted in tail DNA extracts by 
polymerase chain reaction (PCR) and the products were resolved through gel electrophoresis and 
visualized under UV light. For genotyping, forward primer Notch2Lox gtF 5’- 
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CCCTTCTCTCTGTGCCGTAG -3’ and reverse primer Notch2Lox gtR 5’- 
CTCAGAGCCAAAGCCTCACTG -3’ were used. (Integrated DNA Technologies; IDT, 
Coralville, IA).  
 
Chondrocyte Cultures 
The joints were dissected from the hind limbs of both male and female three- to four-day-old 
Notch2tm1.1Ecan mice and Notch2wt/wt mice in phosphate-buffered saline (PBS), and placed in 
Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, Waltham, MA). The 
chondrocyte-enriched cells were trypsinized in 0.25% trypsin-EDTA at 37°C for 40 minutes, and 
then incubated while rotating in 200 units/mL of collagenase type 2-DMEM mix (Worthington 
Biochemical Corporation, Lakewood, NJ) for 2 hours at 37°C, as described (26). The digested 
cartilage was homogenized, strained through a 70 µM membrane, and centrifuged for 5 minutes. 
Cells were suspended in DMEM with 10% fetal bovine serum (FBS) and 100 µg/mL ascorbic acid 
(Sigma-Aldrich, St. Louis, MO) at 37°C and cultured in a 5% CO2 atmosphere, as described (26). 
The culture was confirmed to consist of chondrocytes because gene markers characteristic of 
chondrocytes were present, such as Type 2 collagen, type 10 collagen, and aggrecan.  Cells were 
then seeded on plates coated with JAGGED1 to activate Notch receptors. Either control ASO, 
Notch2 ASO, or Notch26955C>T ASO (Ionis Pharmaceuticals, Carlsbad, California) were added to 
the culture medium in varying amounts of dose and time, as stated in figure legends. 
 
Notch2 Expression In Vivo 
Control and Notch2 ASOs were injected subcutaneously at 50 mg/kg into 1–2-month-old 
Notch2wt/wt mice and Notch2tm1.1Ecan mice. The animals were sacrificed 72 hours later, femoral 
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heads were isolated, and RNA was subsequently extracted and reverse-transcribed in the presence 
of specific primers for Notch2 and Notch26955C>T, as described (21). 
 
RNA Integrity and Real Time Reverse Transcription Polymerase Chain Reaction 
RNA was extracted from cell cultures with the RNeasy kit (Qiagen, Valencia, CA) and RNA 
concentrations were measured via nanodrop spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA). The RNA integrity of a random sample from each group was assessed with a Bio-
Rad Experion microfluidic electrophoresis system (Bio-Rad, Hercules, CA). All RNA that was 
analyzed had a quality indicator number higher than 9.0. RNA was treated with DNase and 
subsequently reverse-transcribed using the iScript RT-PCR kit (Bio-Rad). Once converted to 
cDNA, the samples were amplified in the presence of specific primers (Table 1) and SYBR green 
in a Bio-Rad CFX96 thermal cycler. Copy number was estimated by comparison to a standard 
curve of a serial dilution of cDNA for Notch2 (from Open Biosystems, Huntsville, AL), Hes1 
(from American Type Culture Collection; ATCC, Manassas, VA), Hey1 and Hey2 (from T. Iso, 
Los Angeles, CA), and HeyL (from D. Srivastava, Dallas, TX). Copy number was corrected for 
expression of Rpl38. Rpl38 cDNA was obtained from ATCC. To determine the expression of the 
mutant transcript, DNase-treated RNA was reverse-transcribed in the presence of specific primers 
for the mutant transcript, with a 6955C>T substitution in Notch2, and with SYBR Universal Probe 
and custom TaqMan assay probe, as described (7). The Notch26955C>T transcript copy number was 
measured and corrected for Rpl38 expression. Fluorescence was monitored during every PCR 











Reverse 5’- GTAGCTGCCCTGAGTGTTGTGG -3’ 
Rpl38 





















Table 1. Primers used for qRT-PCR determinations. 
 
Statistics 
Data are expressed as means ± standard deviation (SD), and statistical differences were determined 
by unpaired t-test for Figures 3, 4, 5, 7, and 8, and by two-way ANOVA with Tukey’s multiple 






Effect of Notch2 ASOs on Notch2 and Notch26955C>T Expression in Chondrocytes  
To determine the most effective duration of treatment, a time course experiment was conducted. 
In cells from Notch2tm1.1Ecan mice, 10 µM control or Notch2 ASO were administered, and cells 
cultured for 24 to 96 hours after the addition of the ASO. Notch2 mRNA expression increased 
when cells were cultured for 72 hours in the presence of control ASO compared to cells cultured 
for 24 hours. Addition of Notch2 ASO prevented the increase in Notch2 expression so that Notch2 
ASO inhibited Notch2 expression with an effect that was maximal after 72 hours, proven 
significant by unpaired t-test (Figure 3). 
 
Figure 3. Time course experiment. Effect of 10 µM control or Notch2 ASO in chondrocytes from 
Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates for varying time periods. Data are shown 
as Notch2 copy number corrected for Rpl38 expression. Values are means ± SD; n=3. * 
Significantly different between the same dose of control ASO and Notch2 ASO after a certain 
elapsed time, p < 0.05 by unpaired t-test. 
 
To determine the effective dose of Notch2 ASOs, doses of 0, 5, 10, and 20 µM control and Notch2 
ASO were added to chondrocyte cultures from Notch2tm1.1Ecan mice for 72 hours. Control ASO did 
not have an effect on Notch2 expression. Administration of Notch2 ASO at doses of 5, 10, and 20 
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µM to cells of Notch2tm1.1Ecan mice significantly decreased Notch2 expression, with a maximal 
decrease at a dose of 20 µM (Figure 4A). Notch2tm1.1Ecan chondrocytes, cultured with 20 µM of 
Notch2 ASO, showed significantly decreased expression of the HCS mutant transcript, 
Notch26955C>T, compared to cells cultured with equivalent dose of control ASO (Figure 4B). 
A                                                                             B 
   
Figure 4. Effect of varying doses of control or Notch2 ASO in chondrocytes from Notch2tm1.1Ecan 
mice cultured on JAGGED1-coated plates for 72 hours. Panel A shows Notch2 copy number 
corrected for Rpl38 expression. Panel B shows expression of the HCS 6955C>T point mutation, 
Notch26955C>T, as copy number corrected for Rpl38 expression. Values are means ± SD; n=3. * 
Significantly different between the same dose of control ASO and Notch2 ASO, p < 0.05 by 
unpaired t-test 
 
To compare the effect of Notch2 ASOs on cells from wild type and mutant mice, expression of 
Notch2 and Notch26955C>T transcripts were measured in wild type and mutant cells. In chondrocytes 
from both Notch2wt/wt mice and Notch2tm1.1Ecan mice, Notch2 ASOs significantly decreased Notch2 
mRNA expression at 20 µM, decreasing by 80% in mutant cells (Figure 5A-B). Chondrocytes 
isolated from Notch2wt/wt mice did not express the HCS mutant transcript, Notch26955C>T. In cells 
from Notch2tm1.1Ecan mice, expression of Notch26955C>T decreased by 50% when chondrocytes were 





B                C     
        
Figure 5. Effect of varying doses of control or Notch2 ASOs in chondrocytes from Notch2wt/wt 
mice and Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates for 72 hours. Panel A shows 
expression of Notch2 as copy number corrected for Rpl38 expression in Notch2wt/wt mice, Panel B 
shows expression of Notch2 as copy number corrected for Rpl38 expression in Notch2tm1.1Ecan 
mice, and Panel C shows expression of Notch26955C>T as copy number corrected for Rpl38 
expression in Notch2tm1.1Ecan mice. Notch26955C>T was not detected in chondrocytes of Notch2wt/wt 
mice. Values are means ± SD; n=3. * Significantly different between the same dose of control 
ASO and Notch2 ASO, p < 0.05 by unpaired t-test. 
 
 
Effect of Notch2 ASOs on the Expression of Notch Target Genes in Chondrocytes 
We asked the question as to whether Notch signaling is present in chondrocytes. Expression of 
the Notch target genes Hes1, Hey1, Hey2, and HeyL was significantly increased in Notch2tm1.1Ecan 
chondrocytes, compared to chondrocytes from Notch2wt/wt mice when cultured on JAGGED1-
coated plates. (Figure 6). Expression of Hes1, Hey1, Hey2, and HeyL in chondrocytes from 
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Notch2tm1.1Ecan mice decreased significantly when treated with 20 μM Notch2 ASO (Figures 6A-
D). 
A             B 
                  
C              D 
                     
Figure 6. Effect of 20 µM control or Notch2 ASO on Hes1, Hey1, Hey2, and HeyL expression in 
chondrocytes from Notch2wt/wt mice and Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates 
for 72 hours. Panels A-D show data expressed as copy number of Hes1, Hey1, Hey2, and HeyL, 
corrected for Rpl38 expression. Values are means ± SD; n=3. * Significantly different between 
control ASO and Notch2 ASO, p < 0.05; # significantly different between Notch2wt/wt mice and 






Effect of Mutant-Specific Notch26955C>T ASO on Mutant Notch26955C>T Transcript Expression 
Expression of Notch2 did not change in chondrocytes isolated from Notch2wt/wt mice and 
Notch2tm1.1Ecan mice treated with mutant specific Notch26955C>T ASO (Figure 7A). In contrast, 
expression of the mutant transcript, Notch26955C>T, significantly decreased by 83% in chondrocytes 
from Notch2tm1.1Ecan mice when treated with the mutant specific Notch26955C>T ASO. As expected, 
expression of Notch26955C>T was not detected in chondrocytes from Notch2wt/wt mice treated with 
control or Notch26955C>T ASO (Figure 7B). 
A                 
 
B       C 
          
 
Figure 7. Effect of varying doses of mutant-specific Notch26955C>T ASO in chondrocytes from 
Notch2wt/wt mice and Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates for 72 hours. Panel 
A shows expression of Notch2 copy number corrected for Rpl38 expression in Notch2wt/wt mice, 
Panel B shows Notch2 copy number corrected for Rpl38 expression in Notch2tm1.1Ecan mice, and 
Panel C shows expression of Notch26955C>T copy number corrected for Rpl38 expression. Values 
are means ± SD; n=3. * Significantly different between the same dose of control ASO and Notch2 
ASO, p < 0.05 by unpaired t-test.   
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Effect of Notch2 ASOs on Notch2 and Notch26955C>T Expression In Vivo 
Expression of Notch2 mRNA from Notch2wt/wt chondrocytes decreased by 22% following 
subcutaneous injection of Notch2 ASO, although the effect did not reach statistical significance. 
Expression of Notch2 mRNA from Notch2tm1.1Ecan chondrocytes showed a significant decrease 
following injection of Notch2 ASO (Figure 8A). Expression of Notch26955C>T mRNA was not 
detected in cartilage from Notch2wt/wt mice, as expected. In Notch2tm1.1Ecan mice, expression of 
Notch26955C>T transcript decreased by 36% when mice were injected with Notch2 ASO compared 
to control ASO, although the effect did not reach statistical significance (Figure 8B). 
A                                                                             B 
             
Figure 8. Effect of control and Notch2 ASOs on Notch2 and Notch26955C>T expression in 
Notch2wt/wt mice and Notch2tm1.1Ecan mice in vivo. Data are shown as copy number of Notch2, Panel 
A, and copy number of Notch26955C>T, Panel B, corrected for Rpl38 expression. Values are means 
± SD; n=3. * Significantly different between the same dose of control ASO and Notch2 ASO, p < 





In this study, we report that wild type Notch2 ASO and mutant specific Notch2 ASO downregulate 
Notch2 and Notch26955C>T expression, respectively, in chondrocyte cultures from Notch2tm1.1Ecan 
mice. Notch2 ASO had the same effect on the expression of Notch2 mRNA in Notch2wt/wt mice 
and Notch2tm1.1Ecan mice. 
 
Previous work shows evidence of increased NOTCH2 signaling in cells of osteoblast, osteoclast, 
and osteocyte cell cultures from Notch2tm1.1Ecan mice, and suppression of NOTCH2 activation upon 
addition of Notch2 ASOs in these cultures (21). We raised the question as to whether Notch 
signaling was present in cartilage tissue. Expression of the Notch target genes Hes1, Hey1, Hey2, 
and HeyL was amplified in Notch2tm1.1Ecan mice compared to Notch2wt/wt mice, conforming to the 
gain-of-function NOTCH2 mutation expected in HCS. Notch2 ASO significantly decreased 
mRNA expression of Hes1, Hey1, Hey2, and HeyL in Notch2tm1.1Ecan mice, although levels of 
mRNA expression in ASO-treated Notch2tm1.1Ecan chondrocytes were not as low as the mRNA 
levels found in chondrocytes from Notch2wt/wt mice. This raises the concern that the Notch2 ASO 
is not completely effective in targeting the Notch signaling pathway. 
 
Transcripts from the mutant gene Notch26955C>T, indicative of HCS, were present in cells from 
Notch2tm1.1Ecan mice, but not in Notch2wt/wt mice. Notch26955C>T mutant ASOs downregulated 
Notch26955C>T in Notch2tm1.1Ecan mice but did not downregulate Notch2, indicating that it is specific 
to the mutant transcript. This is consistent with the results of previous work, which found that 
Notch26955C>T mRNA was present in osteocyte-enriched cultures only from Notch2tm1.1Ecan mice 
and found that Notch2 ASOs suppressed Notch26955C>T mRNA levels in these cultures (21). 
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Previous work showed a 50% downregulation of Notch2 mRNA in the spleen, kidney, femur, and 
liver after subcutaneous administration of Notch2 ASO (21). In the present work, Notch2 ASOs 
did not downregulate Notch2 in cartilage when administered in vivo subcutaneously as efficiently 
as they did in vitro. This could be due to the limited vascularization of cartilage tissue, making it 
difficult for the ASO to access this tissue. In an inflammatory disease state, however, systemic 
administration of ASOs may be more effective, an effect that could be studied in the future.  
 
Additional ways to apply ASOs in vivo are possible. Previous work revealed that mice harboring 
the HCS mutation are sensitized to osteoarthritis (26). Because of this, ASOs may be effective in 
vivo if they are applied in a localized fashion. This would directly deliver ASOs to cartilage tissue. 
Although a systemic application would be more practical, local administration of ASO could be 
more successful. Also, it may be worth studying the effects of an in vivo ASO applied for a longer 
duration than 72 hours. 
 
CONCLUSION 
In conclusion, gain-of-function NOTCH2 signaling, indicative of HCS, is present in chondrocytes 
from Notch2tm1.1Ecan mice. Notch2 ASOs downregulate Notch2 mRNA in vitro in chondrocyte 
cultures from Notch2wt/wt mice and Notch2tm1.1Ecan mice, and Notch26955C>T ASOs downregulate 
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